Key facts: Pfizer gains antitrust approval for Metsera; faces lawsuits
Meno di 1 minuto di lettura
- Pfizer received early U.S. antitrust approval for its $7.3 billion Metsera acquisition, with the FTC ending the waiting period, enabling the company to move forward without extra review.1
- Pfizer is suing in Delaware against Metsera and Novo Nordisk over Novo's $8.5 billion takeover bid, claiming it threatens Pfizer's $7.3 billion merger agreement and violates antitrust laws.234
- A federal judge has ordered Pfizer and 35 other drugmakers to face an antitrust lawsuit over alleged price-fixing on 80 generic drugs from 2009 to 2016.5